Darunavir Viatris
HIV Protease Inhibitor — Antiretroviral Film-Coated Tablets
Darunavir Viatris is a prescription antiretroviral medicine containing darunavir, an HIV protease inhibitor. It is used in combination with a low dose of ritonavir and other HIV medicines to treat HIV-1 infection in adults and children aged 3 years and older weighing at least 15 kg. Darunavir works by reducing the amount of HIV in the body, thereby improving immune function and lowering the risk of HIV-associated diseases.
Quick Facts
Key Takeaways
- Darunavir Viatris is an HIV protease inhibitor that must always be taken with ritonavir (pharmacokinetic enhancer) and food to work effectively.
- It is approved for adults and children aged 3 years and older (weighing at least 15 kg) as part of combination antiretroviral therapy.
- Darunavir has numerous drug interactions — always inform your doctor about all other medications, supplements, and herbal products you are taking.
- The most common side effect is diarrhea; serious but rare side effects include severe skin reactions and liver problems.
- Darunavir does not cure HIV. Continuous, lifelong treatment is necessary to suppress the virus and maintain immune health.
What Is Darunavir Viatris and What Is It Used For?
Darunavir Viatris belongs to a class of antiretroviral medicines known as protease inhibitors (PIs). It contains the active ingredient darunavir, which was first approved by the United States Food and Drug Administration (FDA) in 2006 and subsequently by the European Medicines Agency (EMA). As a generic formulation manufactured by Viatris, it provides the same active substance as the originator brand PREZISTA.
HIV (human immunodeficiency virus) uses a protease enzyme to cut large polyprotein chains into smaller functional proteins that are essential for the assembly of new viral particles. Darunavir selectively binds to this protease enzyme and blocks its activity. By inhibiting the HIV protease, darunavir prevents the virus from producing mature, infectious viral particles. This reduces the viral load in the blood, allowing the immune system to recover and function more effectively.
Darunavir is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. According to the Department of Health and Human Services (DHHS) HIV treatment guidelines and the European AIDS Clinical Society (EACS) guidelines, boosted darunavir is considered a preferred or recommended protease inhibitor for both treatment-naive and treatment-experienced patients. It has a high genetic barrier to resistance, meaning that HIV must accumulate multiple mutations before it can become resistant to darunavir.
This medicine is prescribed to adults and to children aged 3 years and older who weigh at least 15 kg. In treatment-naive patients (those who have never taken antiretroviral drugs before), darunavir is typically administered once daily together with ritonavir. In treatment-experienced patients, the dosing regimen (once or twice daily) depends on the patient's treatment history and resistance profile, as determined by the prescribing physician.
Darunavir must always be taken together with a low dose of ritonavir (a pharmacokinetic enhancer). Ritonavir inhibits the liver enzyme CYP3A4 that would otherwise rapidly metabolize darunavir, thereby increasing darunavir's blood levels to therapeutic concentrations. Without ritonavir, darunavir cannot suppress HIV effectively.
What Should You Know Before Taking Darunavir Viatris?
Contraindications
Darunavir Viatris must not be used in the following situations:
- Hypersensitivity to darunavir, ritonavir, or any of the excipients contained in the formulation.
- Severe hepatic impairment (Child-Pugh Class C). Patients with significant liver disease should undergo a thorough hepatic assessment before initiating darunavir therapy. Darunavir is extensively metabolized by the liver, and impaired hepatic function can lead to dangerously elevated drug levels.
- Co-administration with certain medicines that have narrow therapeutic windows and whose plasma levels may be significantly increased by darunavir/ritonavir, leading to serious or life-threatening adverse events (see Drug Interactions section).
The following medicines must never be taken together with darunavir/ritonavir due to the risk of serious or life-threatening adverse reactions: avanafil, oral midazolam, triazolam, cisapride, ergot alkaloids (ergotamine, dihydroergotamine, ergonovine, methylergonovine), pimozide, quetiapine, lurasidone, sertindole, amiodarone, dronedarone, quinidine, ranolazin, lovastatin, simvastatin, lomitapide, rifampicin, lopinavir/ritonavir, elbasvir/grazoprevir, alfuzosin, sildenafil (for pulmonary hypertension), ticagrelor, naloxegol, dapoxetine, domperidone, and products containing St. John's wort (Hypericum perforatum).
Warnings and Precautions
Before starting and during treatment with darunavir, patients should discuss the following with their healthcare provider:
Skin reactions: Patients taking darunavir may develop skin rash. While the rash is usually mild or moderate, in rare cases it can become severe and potentially life-threatening. Stevens-Johnson syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported in rare cases. If a rash develops, patients should contact their doctor immediately. Rash may occur more frequently in patients taking both darunavir and raltegravir.
Liver disease: Patients with pre-existing liver conditions, including chronic hepatitis B or C infection, have an increased risk of developing hepatic adverse events. The prescribing physician should order liver function tests before initiating treatment and at regular intervals during therapy. Symptoms of liver problems include yellowing of the skin or eyes (jaundice), dark-colored urine, pale stools, nausea, vomiting, loss of appetite, or pain in the right upper abdomen.
Diabetes: Darunavir may increase blood glucose levels. Patients with diabetes or pre-diabetes should monitor their blood sugar more frequently and discuss glycemic management with their doctor.
Immune reconstitution inflammatory syndrome (IRIS): In patients with advanced HIV infection who have previously had opportunistic infections, signs and symptoms of inflammation from those prior infections may emerge shortly after starting antiretroviral therapy. This is believed to result from the recovering immune system mounting a response against previously subclinical infections. Autoimmune disorders (such as Graves' disease, polymyositis, or Guillain-Barré syndrome) may also occur months after treatment initiation.
Hemophilia: Protease inhibitors, including darunavir, may increase the risk of bleeding in patients with hemophilia type A or B.
Sulfonamide allergy: Darunavir contains a sulfonamide moiety. Patients with a known allergy to sulfonamide-containing medicines should inform their doctor, although the clinical relevance of cross-reactivity is uncertain.
Osteonecrosis: Patients on long-term combination antiretroviral therapy may be at risk for osteonecrosis (death of bone tissue due to loss of blood supply), particularly in the hips, knees, and shoulders. Risk factors include corticosteroid use, alcohol consumption, severe immunosuppression, and high body mass index (BMI).
Pregnancy and Breastfeeding
Women who are pregnant or planning to become pregnant should inform their healthcare provider immediately. The use of darunavir with ritonavir during pregnancy should only occur when specifically directed by a physician. Darunavir must not be taken with cobicistat during pregnancy because cobicistat does not achieve adequate boosting levels during the second and third trimesters, which could lead to subtherapeutic darunavir levels and risk of viral rebound and mother-to-child transmission.
Breastfeeding is not recommended for women living with HIV, regardless of antiretroviral therapy, because HIV can be transmitted to the infant through breast milk. The World Health Organization (WHO) recommendations on breastfeeding and HIV vary by region and resource setting; however, in high-resource settings, formula feeding is generally recommended to eliminate the risk of transmission.
Elderly Patients
Clinical experience with darunavir in patients aged 65 years and older is limited. Elderly patients should discuss the use of Darunavir Viatris with their physician, as they may have a higher likelihood of hepatic, renal, or cardiac impairment, as well as a greater probability of concomitant medication use that could interact with darunavir.
How Does Darunavir Viatris Interact with Other Drugs?
Darunavir is primarily metabolized by cytochrome P450 3A4 (CYP3A4), and ritonavir is a potent inhibitor of CYP3A4. When taken together, ritonavir dramatically increases darunavir blood levels. However, this CYP3A4 inhibition also affects the metabolism of many other drugs, leading to potentially dangerous elevations in the blood levels of co-administered medications. Conversely, potent CYP3A4 inducers can reduce darunavir levels, potentially rendering HIV treatment ineffective.
Patients should always provide a complete list of all medications — including over-the-counter drugs, herbal supplements, and recreational substances — to their prescribing physician. The tables below summarize key interactions.
Major Interactions (Contraindicated)
The following medicines must never be taken together with darunavir/ritonavir:
| Medicine | Therapeutic Use | Reason for Contraindication |
|---|---|---|
| Rifampicin | Tuberculosis treatment | Potent CYP3A4 inducer; reduces darunavir levels by approximately 80% |
| Simvastatin, Lovastatin | Cholesterol lowering | Risk of severe rhabdomyolysis due to markedly increased statin levels |
| Oral Midazolam, Triazolam | Sedatives / anxiolytics | Risk of excessive and prolonged sedation or respiratory depression |
| Ergot alkaloids | Migraine treatment | Risk of acute ergot toxicity including vasospasm and ischemia |
| Amiodarone, Dronedarone, Quinidine | Cardiac arrhythmias | Risk of serious cardiac arrhythmias due to elevated drug levels |
| Pimozide, Quetiapine, Lurasidone | Psychiatric conditions | Risk of serious adverse effects including QT prolongation |
| Cisapride | Gastrointestinal motility | Risk of cardiac arrhythmias |
| St. John's Wort | Herbal antidepressant | CYP3A4 inducer; may significantly reduce darunavir plasma levels |
| Ticagrelor | Antiplatelet agent | Increased bleeding risk due to elevated ticagrelor levels |
| Avanafil | Erectile dysfunction | Significant increase in avanafil exposure; risk of adverse effects |
Interactions Requiring Dose Adjustment or Monitoring
Many other medicines can be co-administered with darunavir/ritonavir but may require dose adjustments or additional monitoring. Key categories include:
- Cardiovascular medicines (amlodipine, diltiazem, nifedipine, verapamil, metoprolol, carvedilol) — increased blood levels and enhanced therapeutic or adverse effects.
- Anticoagulants (warfarin, apixaban, dabigatran, rivaroxaban, edoxaban) — altered anticoagulant effects requiring close INR or clinical monitoring.
- Hormonal contraceptives — darunavir may reduce the effectiveness of estrogen-based hormonal contraceptives. Alternative non-hormonal methods of contraception are recommended.
- Statins (atorvastatin, pravastatin, rosuvastatin) — use with caution at the lowest possible dose with monitoring for muscle toxicity.
- Immunosuppressants (ciclosporin, tacrolimus, sirolimus, everolimus) — significantly increased levels requiring therapeutic drug monitoring.
- Corticosteroids (inhaled budesonide, fluticasone, systemic dexamethasone) — risk of Cushing syndrome and adrenal suppression due to elevated corticosteroid levels.
- Antiepileptics (phenobarbital, phenytoin, carbamazepine) — may reduce darunavir levels while darunavir may alter antiepileptic levels.
- PDE5 inhibitors (sildenafil, tadalafil, vardenafil for erectile dysfunction) — use reduced doses with careful monitoring.
- Opioids (fentanyl, oxycodone, tramadol, methadone, buprenorphine) — dose adjustments may be needed due to altered opioid metabolism.
- Antifungals (itraconazole, posaconazole, fluconazole, isavuconazole) — bidirectional interactions; voriconazole should only be used after medical evaluation.
- Hepatitis C antivirals (glecaprevir/pibrentasvir) — increased levels of hepatitis C drugs; monitor for hepatotoxicity.
- Antidepressants (sertraline, paroxetine, amitriptylin, trazodone) — potential for increased antidepressant levels; dose titration may be needed.
- Antimalarials (artemether/lumefantrin) — altered drug levels requiring clinical monitoring.
- Antineoplastics (dasatinib, nilotinib, vincristine, vinblastine, irinotecan, everolimus) — increased toxicity risk; oncology-infectious disease consultation recommended.
Darunavir boosted with ritonavir can generally be combined with nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs, though efavirenz may reduce darunavir levels), CCR5 antagonists (e.g., maraviroc, with dose adjustment), and integrase strand transfer inhibitors (INSTIs). However, darunavir/ritonavir must not be used with other protease inhibitors, especially the lopinavir/ritonavir combination.
What Is the Correct Dosage of Darunavir Viatris?
Darunavir Viatris must always be taken exactly as prescribed by the healthcare provider. The following dosing recommendations are based on approved prescribing information. Patients should never alter the dose, change the dosing frequency, or stop treatment without consulting their doctor, even if they feel well.
Adults
For treatment-naive adults or treatment-experienced adults with no darunavir resistance-associated mutations, the recommended dose is 800 mg darunavir (one 800 mg tablet, or two 400 mg tablets) taken once daily together with 100 mg ritonavir and food.
For treatment-experienced adults with one or more darunavir resistance-associated mutations, or when the resistance pattern is unknown, the recommended dose is 600 mg darunavir (one 600 mg tablet) taken twice daily (morning and evening) together with 100 mg ritonavir at each dose, with food.
| Patient Type | Darunavir Dose | Ritonavir Dose | Frequency |
|---|---|---|---|
| Treatment-naive | 800 mg | 100 mg | Once daily with food |
| Treatment-experienced (no DRV RAMs) | 800 mg | 100 mg | Once daily with food |
| Treatment-experienced (with DRV RAMs) | 600 mg | 100 mg | Twice daily with food |
Children (3 Years and Older, ≥15 kg)
The pediatric dose is determined by body weight. The prescribing physician will determine whether a once-daily or twice-daily regimen is appropriate based on the child's treatment history. The tables below summarize the weight-based dosing recommendations.
| Body Weight | Darunavir Dose | Ritonavir Dose |
|---|---|---|
| 15 to 30 kg | 600 mg once daily | 100 mg once daily |
| 30 to 40 kg | 675 mg once daily | 100 mg once daily |
| Over 40 kg | 800 mg once daily | 100 mg once daily |
| Body Weight | Darunavir Dose | Ritonavir Dose |
|---|---|---|
| 15 to 30 kg | 375 mg twice daily | 50 mg twice daily |
| 30 to 40 kg | 450 mg twice daily | 60 mg twice daily |
| Over 40 kg | 600 mg twice daily | 100 mg twice daily |
Children should always take darunavir together with ritonavir and food. The tablets should be swallowed whole with a drink such as water or milk. Alternative formulations (e.g., oral suspension) may be more suitable for younger children or those who have difficulty swallowing tablets.
Darunavir should not be used in children under 3 years of age or those weighing less than 15 kg.
Missed Dose
If a dose is missed and the patient notices within 6 hours of the scheduled time, the dose should be taken immediately with ritonavir and food. If more than 6 hours have elapsed, the missed dose should be skipped and the next dose taken at the regular time. A double dose should never be taken to compensate for a missed one.
If the patient vomits within 4 hours of taking darunavir and ritonavir, another dose should be taken with food as soon as possible. If vomiting occurs more than 4 hours after ingestion, no additional dose is needed until the next scheduled time.
Overdose
In the event of an overdose, patients should contact a healthcare provider or poison control center immediately. There is no specific antidote for darunavir. Treatment of overdose consists of general supportive measures, including monitoring of vital signs and clinical status. If necessary, elimination of unabsorbed drug may be achieved by emesis or gastric lavage. Since darunavir is highly protein-bound, dialysis is unlikely to be effective in removing the drug from the bloodstream.
Darunavir must be taken with food. The absorption of darunavir is significantly reduced when taken on an empty stomach. The type of food does not matter — both light snacks and full meals are acceptable, as long as the drug is not taken on an empty stomach.
What Are the Side Effects of Darunavir Viatris?
Like all medicines, Darunavir Viatris can cause side effects, although not everyone experiences them. During HIV treatment, weight gain and increased levels of lipids and glucose in the blood may occur, which is partly related to restored health and lifestyle factors, but may also be associated with the antiretroviral medicines themselves. Your doctor will test for these changes regularly.
The frequency of side effects is categorized according to the following convention:
Very Common
Affects more than 1 in 10 people
- Diarrhea
Common
Affects up to 1 in 10 people
- Nausea, vomiting
- Abdominal pain or bloating
- Indigestion, flatulence
- Headache
- Fatigue, dizziness, drowsiness
- Numbness, tingling, or pain in hands and feet (peripheral neuropathy)
- Weakness, difficulty sleeping
- Skin rash
- Diabetes (elevated blood glucose)
Uncommon
Affects up to 1 in 100 people
- Chest pain, ECG changes, rapid heartbeat
- Breathing difficulties, cough, nosebleed, throat irritation
- Inflammation of the stomach or mouth, heartburn, dry mouth, constipation
- Pancreatitis (inflammation of the pancreas)
- Kidney failure, kidney stones, frequent urination
- Hives (urticaria), severe swelling of skin (angioedema), eczema, excessive sweating, hair loss, acne
- Muscle pain, muscle cramps, muscle weakness, joint pain
- Osteonecrosis (bone tissue death), osteoporosis
- High blood pressure, flushing
- Hypothyroidism (reduced thyroid function)
- Erectile dysfunction, breast enlargement
- Depression, anxiety, abnormal dreams, decreased libido
- Fever, peripheral edema, irritability
Rare
Affects up to 1 in 1,000 people
- DRESS syndrome (severe rash with fever, facial swelling, lymph node enlargement, eosinophilia, and organ involvement)
- Heart attack, slow heart rate, palpitations
- Visual disturbances
- Confusion, disorientation, mood changes, restlessness
- Fainting, seizures, altered or lost taste sensation
- Mouth ulcers, vomiting blood, lip inflammation, dry lips, coated tongue
- Muscle and joint stiffness
- Darunavir crystals in the kidneys causing renal disease
- Chills, feeling abnormal
Liver Problems
Liver problems, sometimes severe, have been reported with darunavir use. Your doctor should perform liver function blood tests before starting treatment. Patients with chronic hepatitis B or C infection require more frequent monitoring because they are at increased risk for hepatotoxicity. Signs and symptoms of liver problems include:
- Yellowing of the skin or whites of the eyes (jaundice)
- Dark (tea-colored) urine
- Pale stools
- Nausea, vomiting, loss of appetite
- Pain, aching, or discomfort on the right side below the ribs
If you experience any of these symptoms, contact your healthcare provider immediately.
Metabolic Changes During HIV Treatment
During antiretroviral therapy, body fat redistribution (lipodystrophy), elevated cholesterol and triglyceride levels, and insulin resistance may occur. These metabolic changes are a class effect of protease inhibitors and are monitored through regular blood tests. Your doctor may recommend dietary modifications, exercise, or lipid-lowering medications if needed.
Contact your doctor or seek emergency care immediately if you experience: severe skin rash with blisters or peeling, signs of liver damage (jaundice, dark urine), signs of pancreatitis (severe abdominal pain radiating to the back), signs of a severe allergic reaction (swelling of the face, lips, or throat, difficulty breathing), or muscle weakness progressing from the extremities toward the trunk.
How Should You Store Darunavir Viatris?
Darunavir Viatris does not require any special storage conditions. Store the medicine at room temperature, protected from excessive heat and moisture. Keep the medicine in its original packaging until use.
- Keep out of sight and reach of children.
- Do not use this medicine after the expiry date stated on the carton and container after EXP. The expiry date refers to the last day of that month.
- For bottles: use within 100 days after first opening.
- Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help protect the environment.
What Does Darunavir Viatris Contain?
Active Substance
Each film-coated tablet contains 600 mg or 75 mg of darunavir.
Inactive Ingredients (Excipients)
The tablet core contains: colloidal anhydrous silica, microcrystalline cellulose, crospovidone, sodium starch glycolate, hypromellose, and magnesium stearate. The film coating contains: polyvinyl alcohol (partially hydrolyzed), titanium dioxide (E171), macrogol, and talc.
Appearance and Packaging
Darunavir Viatris 75 mg film-coated tablets are white to off-white, oval-shaped tablets with two curved sides, debossed with "M" on one side and "DV1" on the other. They are available in blister packs of 480 tablets and plastic bottles of 480 tablets. Not all pack sizes may be marketed.
This medicine contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free.
Other Brand Names
Darunavir is also marketed under other brand names including PREZISTA (the originator brand by Janssen), Darunavir STADA, Darunavir Sandoz, and Darunavir Medical Valley. All contain the same active ingredient and work in the same way.
Can You Drive While Taking Darunavir Viatris?
Dizziness and drowsiness have been reported as side effects of darunavir. While most patients can drive and operate machinery safely, those who experience dizziness, drowsiness, or impaired concentration after taking the medication should refrain from driving or using machinery until these symptoms resolve. It is important to understand how this medicine affects you individually before engaging in activities that require mental alertness.
Frequently Asked Questions
Darunavir Viatris is an antiretroviral medicine used to treat HIV-1 infection. It belongs to the class of drugs called protease inhibitors and must always be taken together with a pharmacokinetic enhancer such as ritonavir, as well as other antiretroviral medicines. It is approved for use in adults and children aged 3 years and older who weigh at least 15 kg.
No. Darunavir must always be taken together with a low dose of ritonavir (or cobicistat as an alternative enhancer in non-pregnant patients). Without ritonavir, darunavir blood levels are too low to effectively suppress the virus. Ritonavir acts as a "booster" by blocking the liver enzyme (CYP3A4) that breaks down darunavir, thereby allowing the drug to reach and maintain therapeutic concentrations in the blood.
The most common side effect is diarrhea, affecting more than 1 in 10 people. Other common side effects (affecting up to 1 in 10 people) include nausea, vomiting, abdominal pain, headache, fatigue, dizziness, peripheral neuropathy (numbness or tingling in the extremities), and skin rash. Most of these side effects are mild to moderate and tend to improve over time. If you experience persistent or worsening side effects, consult your doctor.
No, darunavir does not cure HIV. It is part of combination antiretroviral therapy (ART) that suppresses HIV replication to undetectable levels in the blood. This allows the immune system to recover and function effectively, greatly reducing the risk of HIV-related illnesses and transmission to others. Treatment must be continued for life. Stopping treatment can lead to viral rebound and immune system decline. With consistent treatment, most people with HIV can achieve a normal life expectancy.
If you realize within 6 hours of your scheduled dose time, take the missed dose immediately together with ritonavir and food. If more than 6 hours have passed, skip the missed dose and take your next dose at the regular time. Never take a double dose. If you vomit within 4 hours of taking the medicine, take another dose with food. If vomiting occurs more than 4 hours after, wait until the next scheduled dose. Contact your doctor if you are unsure about what to do or if you frequently miss doses.
There is no specific contraindication against moderate alcohol consumption while taking darunavir. However, both alcohol and darunavir are processed by the liver, so heavy or chronic alcohol use may increase the risk of liver-related side effects. Alcohol may also worsen side effects such as dizziness and drowsiness. Patients with hepatitis B or C co-infection should be especially cautious about alcohol use. Discuss your alcohol intake with your healthcare provider.
References
- European Medicines Agency (EMA). Darunavir — Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed December 2025.
- U.S. Food and Drug Administration (FDA). PREZISTA (darunavir) — Prescribing Information. Available at: www.accessdata.fda.gov. Accessed December 2025.
- World Health Organization (WHO). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. Geneva: WHO; 2021.
- Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Updated 2024. Available at: clinicalinfo.hiv.gov.
- European AIDS Clinical Society (EACS). Guidelines Version 12.0, October 2023. Available at: www.eacsociety.org.
- British National Formulary (BNF). Darunavir Monograph. Available at: bnf.nice.org.uk. Accessed December 2025.
- Clotet B, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis. The Lancet. 2007;369(9568):1169-1178.
- Orkin C, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed adults with HIV-1: EMERALD subgroup analyses. HIV Medicine. 2019;20(8):549-560.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Updated 2024.
Editorial Team
Written by the iMedic Medical Editorial Team, specialists in infectious disease and clinical pharmacology.
Reviewed by the iMedic Medical Review Board according to international guidelines (WHO, EMA, FDA, DHHS, EACS).
All pharmaceutical information is based on approved prescribing information from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), supplemented with current clinical guidelines. Our editorial team follows the GRADE evidence framework and ensures all content reflects the highest available level of evidence. No commercial funding or pharmaceutical sponsorship influences our content.
Published: | Last reviewed: